Newly diagnosed low-grade glioma (LGG) patients have a relatively long survival, but nonetheless ultimately recur. New therapies are therefore being considered for LGG. One approach is the use of Temozolomide, previously reserved for treating high grade glioblastoma. However, early indicators of response are still needed. Here, we investigated response to Temozolomide treatment in an orthotopic LGG mouse model. Using 1H MRS we detected an early decrease in total choline and a surprising increase in both glutamine and glutamine plus glutamate that were associated with ultimate tumor shrinkage. This identifies potential early metabolic biomarkers of response to Temozolomide treatment in LGG.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords